Netupitant clinical trials
Also written CID6451149 and RO 67-3189/000.
How each study uses netupitant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 10 Oct 2014 · AKYNZEO · NDA 205718 (FDA, Drugs@FDA; in a combination)
- European Union
- 27 May 2015 · Akynzeo · EMEA/H/C/003728 (EMA; in a combination)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2017 | 3 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 3
Helsinn Healthcare SA (1) · M.D. Anderson Cancer Center (1) · Instituto Brasileiro de Controle do Cancer (1) · OHSU Knight Cancer Institute (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses netupitant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and VomitingCompletedPhase 2Helsinn Healthcare SANCT03204279Written as NetupitantHow we know
- Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With CancerCompletedPhase 2/3M.D. Anderson Cancer CenterNCT03040726Written as NetupitantHow we know
- Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast CancerCompletedPhase 2Instituto Brasileiro de Controle do CancerNCT04669132Written as NetupitantHow we know
- Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell TransplantCompletedPhase 2OHSU Knight Cancer InstituteNCT03097588Written as NetupitantHow we know
Codes
What other systems call netupitant · ClinicalTrials.gg INT004882
- MeSH (NLM) C508854netupitantConfirmed NLM, Wikidata
- UNII (FDA) 7732P08TIRNETUPITANTConfirmed FDA, NLM, Wikidata
- RxNorm 1552337Confirmed FDA, Wikidata
- Wikidata Q19598139netupitantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C96745NetupitantOne source FDA
- DrugBank DB09048One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C508854 | netupitant | Confirmed NLM, Wikidata |
| UNII (FDA) | 7732P08TIR | NETUPITANT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1552337 | — | Confirmed FDA, Wikidata |
| Wikidata | Q19598139 | netupitant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C96745 | Netupitant | One source FDA |
| DrugBank | DB09048 | — | One source Wikidata |
Also registered as netupitant dihydrochloride (UNII OA7JCO20ZP).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.